Drug combination shows benefit in RAS-driven cancers
Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully.
Apr 3, 2017
0
1
Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully.
Apr 3, 2017
0
1
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit Kong Cheong, from ...
Mar 23, 2015
0
29
Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms ...
Aug 13, 2012
0
0
The body has a built-in system known as autophagy, or 'self-eating,' that controls how cells live or die. Deregulation of autophagy is linked to the development of human diseases, including neural degeneration and cancer.
Aug 1, 2012
0
0
A new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation ...
Nov 21, 2011
0
0